MedTrace Logo

Poor Response to Monoclonal Therapy in Asthma

NCT04114396 · Status: UNKNOWN · Type: OBSERVATIONAL · Enrollment: 50

Last updated 2020-11-03

No results posted yet for this study

Summary

Asthma affects 8% of the entire population. 4-5% of asthma sufferers have severe asthma, characterised by recurrent exacerbations (worsening of symptoms leading to the person having a bout of corticosteroids and/or antibiotics), significant symptoms and lack of response to the most widely used therapy, corticosteroids.

There is now new types of treatments (antibody drugs) which are licensed to manage severe asthma such as Anti-IL5. There is evidence Anti-IL5 and other similar antibody drugs are effective at reducing asthma exacerbations and reduce the need for oral corticosteroids for those that have severe asthma.

However, some patients respond poorly to Anti-IL5 and the investigators would like to find out why this happens. It is hoped that the investigators can identify the mechanism of poor treatment response to Anti-IL5. It is also hoped that the investigators can understand why symptoms worsen to the point of requiring antibiotics and/or steroids (also known as an exacerbation) for those prescribed Anti-IL5.

Conditions

Interventions

DRUG

Anti-IL5 Antibody

Asthma group: Anti-IL5 treatment Control group: No biologic.

PROCEDURE

Bronchoscopy

Optional for both arms

Sponsors & Collaborators

  • University of Nottingham

    lead OTHER

Eligibility

Min Age
18 Years
Max Age
80 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2018-12-31
Primary Completion
2021-06-30
Completion
2021-07-31

Countries

  • United Kingdom

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04114396 on ClinicalTrials.gov